Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nortriptyline vs Double-Dose PPI in Refractory GERD
NCT00539240Phase 3Completed
- Sponsor
- United States Department of Veterans Affairs
- Start
- Apr 2006
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nortriptyline in gastroesophageal reflux disease (GERD) (3 arms), sponsored by United States Department of Veterans Affairs. Primary endpoints: Daytime Heartburn, Number of Days in Week Symptoms Intensity Score < 3 at 6 weeks, Nighttime Heartburn, Number of Days in Week Symptom Activity Score < 3 at 6 weeks and 1 more. Started Apr 2006; status: completed.
02
Drugs
nortriptyline
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT00539240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00539240.